Formation of inclusion bodies in bacterial hosts poses a major challenge for large scale
recovery of bioactive proteins. The process of obtaining bioactive protein from inclusion …

Recombinant proteins expressed as bacterial inclusion bodies (IBs) are now receiving
tremendous attention for many diverse applications in the areas of industrial and medical …

Understanding the structure, functionalities and biology of functional amyloids is an issue of
emerging interest. Inclusion bodies, namely protein clusters formed in recombinant bacteria …

Abstract L-Asparaginase (L-ASNase, EC 3.5. 1.1), an antitumor drug for acute lymphoblastic
leukemia (ALL) therapy, is widely used in the clinical field. Similarly, L-ASNase is also a …

Genetic engineering for heterologous expression has advanced in recent years. Model
systems such as Escherichia coli, Bacillus subtilis and Pichia pastoris are often used as host …

Bacterial inclusion bodies (IBs) consist of unfolded protein aggregates and represent
inactive waste products often accumulating during heterologous overexpression of …

L-asparaginase is an enzyme used as a biopharmaceutical to treat acute lymphoblastic
leukemia. Several adverse effects have been related to L-asparaginase use, so the scientific …

Background The production of therapeutically active single chain variable fragment (scFv)
antibody is still challenging in E. coli due to the aggregation propensity of recombinant …

Abstract l-asparaginase is used as a pivotal agent in treatment of lympho proliferative
disorders and holds an excessive demand for food processing aids. Most of the l …

Recombinant enzyme expression in Escherichia coli is one of the most popular methods to
produce bulk concentrations of protein product. However, this method is often limited by the …